SCN1A and epilepsy: In addition, targeting Kcnt1 transcript in Scn8a mutant mice doubled their lifespan and extended the survival of Scn1a mutant mice, suggesting KCNT1 could be a therapeutic target for the treatment of SCN1A and SCN8A epilepsy [85].